View Author
patient study genotype cancer cyp 3a polymorphism allele effect level concentration variant result activity cyp 2c prostate pharmacokinetic table tacrolimu association treatment tamoxifen therapy group analysis prostate cancer cyp 2d population pharmacol plasma irinotecan signi rotterdam transplant difference sample cyp 3a allele cyp 3a genotype metabolism cytochrome blood model value clearance pharmacogenetic enzyme number serum cyp 2d genotype activin expression breast frequency transplantation rotterdam study netherland subject cohort liver kidney haplotype impdh reference disease signi ficantly recipient cyp 3a activity inhibitor children ratio carrier antigen response vkorc transporter genotyping biopsy docetaxel inhibin method prostate-speci fic antigen
10 Most Recent Publications
|
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
(Article)
Loeb, S. Sokoll, L. Marks, L.S. Mizrahi, I.A. Shin, S.S. Cruz, A.B. Chan, D.W. Roberts, W.L. Catalona, W.J. Broyles, D.L. Bangma, C.H. Schaik, R.H.N. van Klee, G.G. Wei, J.T. Sanda, M.G. Partin, A.W. Slawin, K.M. |
2013-03-22
|
|
Doubt about the feasibility of preemptive genotyping
(Article)
Koch, B.C.P. Schaik, R.H.N. van Gelder, T. van Mathijssen, R.H.J. |
2013-03-01
|
|
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
(Article)
Elens, L. Nieuweboer, A.J.M. Clarke, S.J. Charles, K.A. Graan, A-J.M. de Haufroid, V. Mathijssen, R.H.J. Schaik, R.H.N. van |
2013-01-01
|
|
Reply to F.L. Opdam et al
(Article)
Graan, A-J.M. de Binkhorst, L. Loos, W.J. Schaik, R.H.N. van Verweij, J. Mathijssen, R.H.J. |
2012-02-01
|
|
The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
(Article)
Wildt, S.N. de Schaik, R.H.N. van Soldin, O.P. Brojeni, P.Y. Heiden, I.P. van der Parshuram, C. Nulman, I. Koren, G. |
2011-12-01
|
|
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients
(Article)
Gijsen, V.M.G.J. Mital, S. Schaik, R.H.N. van Soldin, O.P. Heiden, I.P. van der Nulman, I. Koren, G. Wildt, S.N. de |
2011-12-01
|
|
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study
(Article)
Elens, L. Becker, M.L. Haufroid, V. Hofman, A. Visser, L.E. Uitterlinden, A.G. Stricker, B.H.Ch. Schaik, R.H.N. van |
2011-12-01
|
|
ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation
(Article)
Shuker, N. Bouamar, R. Weimar, W. Schaik, R.H.N. van Gelder, T. van Hesselink, D.A. |
2011-10-27
|
|
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
(Article)
Graan, A-J.M. de Teunissen, S.F. Beijnen, J.H. Mathijssen, R.H.J. Vos, F.Y.F.L. de Loos, W.J. Schaik, R.H.N. van Jongh, F.E. de Alphen, R.J. van Holt, B. van der Verweij, J. Seynaeve, C.M. |
2011-08-20
|
|
CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children
(Article)
Rakhmanina, N.Y. Neely, M.N. Schaik, R.H.N. van Gordish-Dressman, H.A. Williams, K.D. Soldin, S.J. Anker, J.N. van den |
2011-08-01
|
